Skip Standard Navigation Links
Centers for Disease Control and Prevention
 CDC Home Search Health Topics A-Z
peer-reviewed.gif (582 bytes)
eid_header.gif (2942 bytes)
 EID Home | Ahead of Print | Past Issues | EID Search | Contact Us | Announcements | Suggested Citation | Submit Manuscript

Volume 9, Number 1, January 2003

Cost Effectiveness of a Potential Vaccine for Human papillomavirus

Gillian D. Sanders* and Al V. Taira*
*Stanford University, Stanford, California, USA

 
 
  Back to article
 

Figure 4. Sensitivity analysis: vaccine cost. Effect of a change in Human papillomavirus (HPV) vaccine cost on the cost effectiveness of vaccination compared with current practice under varying assumptions of vaccine immunity. The triangles represent a vaccine that provides lifetime immunity to high-risk types of HPV. The circles represent a vaccine that requires booster shots every 10 years to remain effective (base-case assumption). The hatches represent a vaccine that requires booster shots every 5 years to remain effective. The dashed lines indicate the $50,000 and $100,000 per quality-adjusted life year cost-effectiveness thresholds. The base-case value of $300 is indicated by the arrow.

 

EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z

This page last reviewed March 20, 2003

Emerging Infectious Diseases Journal
National Center for Infectious Diseases
Centers for Disease Control and Prevention